Understand how fatigue, reduced strength and testosterone results fit together, including repeat testing, SHBG and other health considerations.
Testosterone deficiency, also called male hypogonadism, is a condition assessed by combining compatible symptoms and physical signs with consistently low testosterone in blood tests. The European Association of Urology (EAU) uses this combined approach rather than defining the condition through symptoms or a laboratory result alone.
This article is for informational purposes and is not medical advice. A qualified clinician should assess persistent symptoms and interpret hormone results before making individual decisions about further testing or treatment.
The EAU guideline lists 12 nmol/L (3.5 ng/mL) as a threshold for late-onset hypogonadism. This is the EAU's diagnostic threshold, not a universal cutoff used by every laboratory or guideline.
A diagnostic threshold and a laboratory reference interval serve different purposes. The threshold helps guide an assessment for possible deficiency. It does not provide a complete lower-to-upper reference range or establish an ideal testosterone target for every man.
Biologically, a testosterone blood result describes the concentration measured in the sample. It does not measure how much of someone's tiredness or reduced strength comes from testosterone. That connection requires the clinical assessment described by the EAU.
The distinction matters when a report carries a low flag. The flag identifies a result for interpretation rather than supplying a complete explanation for symptoms. Testostra's guide to placing a low result in diagnostic context addresses that difference in more detail.
The EAU recommends measuring total testosterone in the morning between 07:00 and 10:00, in a fasting state and using a reliable assay. When the initial result falls below its threshold, the guideline calls for measurements on at least two separate occasions before testosterone therapy.
These details are part of the diagnostic process. The useful questions are not limited to whether a value looks low. They also include whether it was collected under the recommended conditions and whether the finding has been confirmed.
A clinician can review the collection details alongside the symptoms that prompted testing. Our explanation of why clinicians confirm results with repeat testing provides further context for that conversation.
Total testosterone is the initial hormone measurement in the EAU approach. Other biomarkers may help when the result does not give a clear clinical picture.
A 2026 review in Nature Reviews Urology notes that free testosterone and sex hormone-binding globulin (SHBG) may clarify selected cases. These include borderline total testosterone results or situations where symptoms and total testosterone do not align.
The practical discussion is therefore about what an additional measurement would clarify. The review supports using these biomarkers to resolve particular uncertainties rather than treating them as an automatic testing package for every complaint of fatigue.
The EAU lists fatigue and reduced energy among possible symptoms of testosterone deficiency. Its symptom table also includes low mood, reduced motivation, sleep disturbance and reduced physical strength or function.
The central limitation belongs here: these symptoms are not exclusive to hypogonadism. The guideline requires them to be interpreted alongside the wider clinical picture and biochemical evidence. A list of matching symptoms is therefore a starting point for assessment rather than a diagnosis.
For an adult man, the useful distinction is between describing a change and explaining its cause. Feeling less able to manage physical tasks describes an experience. Calling that experience testosterone deficiency assigns a cause that still needs investigation.
The same distinction applies to body-composition concerns. A change in weight or body shape belongs in the medical history, but it does not establish a hormone diagnosis by itself. Metabolic health and hormone interpretation need to be considered together.
The EAU distinguishes certain sexual symptoms as more specific than general complaints such as low energy or reduced strength:
This distinction helps clinicians weigh the symptom pattern. It does not replace the guideline's requirement for compatible clinical findings and consistently low testosterone.
A discussion about fatigue should therefore leave room for relevant sexual changes rather than treating energy as the only issue. Likewise, a consultation about sexual function can include sleep and general health. These are parts of one assessment rather than competing explanations that must be chosen in advance.
Testostra's discussion of erection difficulties within a broader assessment explains why a sexual complaint still needs context.
The factors below play different roles. Some can influence hormone results or contribute to hypogonadism. Others offer possible explanations for the fatigue or weakness that led someone to consider testing.
A clinical review on testosterone deficiency identifies obesity, type 2 diabetes and metabolic syndrome as relevant conditions during assessment. It also notes that low SHBG in obesity can affect the interpretation of total testosterone.
This is a useful connection between body composition and biomarkers. The question is not simply whether body weight has changed. It is whether metabolic health and SHBG alter the meaning of the total testosterone result in that clinical setting.
A clinician-led review can connect those findings with the rest of the history. It avoids treating a body-composition change as proof of deficiency or treating a total testosterone number as separate from metabolic health.
The same clinical review lists opioids and glucocorticoids among potentially reversible contributors to secondary hypogonadism. Its differential-diagnosis table also includes glucocorticoid therapy as a possible contributor to reduced muscle strength.
Medication history can therefore matter in more than one way. It may be relevant to the hormone assessment or to the symptom being investigated.
The appropriate next step is a clinician-led medication review. Readers should not stop or alter prescribed medicines because a drug category appears in an article. The review identifies possibilities for assessment rather than proving that a particular prescription explains an individual's symptoms.
The EAU includes disturbed sleep among less-specific symptoms. The clinical review separately lists sleep apnoea as one possible consideration when evaluating fatigue.
These findings support including sleep in the consultation. They do not establish a direct explanation for an individual reader's tiredness.
A useful discussion keeps both issues visible: the sleep complaint itself and the hormone findings being assessed. Labelling fatigue as hormonal before discussing sleep would leave part of the clinical picture unaddressed.
The clinical review lists depression among possible considerations when assessing fatigue and reduced libido. This adds another reason to discuss mood alongside energy and sexual symptoms.
Low mood does not need to be framed as either exclusively hormonal or entirely unrelated to testosterone. The assessment can consider mood concerns and possible hypogonadism together. Testostra's article on the overlap between mental health and hormone concerns offers further background for that conversation.
The review lists physical inactivity, malnutrition and neurological disease among possible considerations for reduced strength. These are clinical prompts rather than evidence for a particular diet or exercise plan to raise testosterone.
For fatigue, the review also identifies anaemia and hypothyroidism as possible considerations. Cardiopulmonary disease appears in that differential assessment too.
Those possibilities are not a ranking of what is most likely for any reader. Their practical value is to keep the evaluation tied to the actual complaint. Reduced strength may require questions about activity and nutrition, while fatigue may lead to a different set of clinical considerations.
The resulting assessment can connect symptoms with medical history, medicines and metabolic health. Appropriately collected hormone measurements then contribute evidence without becoming the sole explanation for every change in wellbeing.
Ask your physician: “What else could explain these symptoms? Was my testosterone result collected under appropriate conditions and does it need confirmation? Could medicines or metabolic health affect its interpretation? Would SHBG or free testosterone add useful context?”
Confusing a testosterone threshold with an explanation for fatigue is a shortcut Testostra addresses through evidence-led hormone education. For men sorting out total testosterone, free testosterone and SHBG, its biomarker coverage places laboratory findings in context while keeping general information separate from individual medical decisions.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra